Guo Mu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guo Mu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Bin Lu
Department of Anesthesiology, Zigong Fourth People's Hospital, Zigong, 643000, Sichuan, China
3 shared publicationsZi-Hang Yu
Department of Anesthesiology, Fushun County People’s Hospital, Zigong, China
3 shared publicationsFei-Xiang Wang
Department of Anesthesiology, The Affiliated Hospital, Southwest Medical University, Luzhou, China
2 shared publicationsJia Fu
Department of Pain Management, Affiliated Hospital of Southwest Medical University, Luzhou, China
2 shared publicationsLiang Nie
Department of Anesthesiology, Fushun County People’s Hospital, Zigong, China
2 shared publicationsQiang Li
Department of Anesthesiology Zigong Fourth People's Hospital 643000 Zigong Sichuan China
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Silicon-based agent alleviating intestinal ischemia/reperfusion injury in mice by inhibiting ferroptosis via activating AMPK-Sirt1 signaling pathway
Ferroptosis is a death mode centered on iron metabolism and lipid peroxidation pathways. Recent studies have shown that inhibiting ferroptosis can alleviate intestinal ischemia/reperfusion (II/R) injury. Hydrogen (H2) can mitigate II/R injury by anti-oxidative stress, while Silicon (Si)-based agent can generate a large amount of H2 in the alkaline environment of the intestine during II/R. However, it is unclear whether Si-based agent can alleviate II/R injury. By establishing a mouse model of II/R injury, we examined the histopathological changes, apoptosis, inflammatory factors, oxidative stress, and ferroptosis levels in the small intestine. We found that the AMPK-Sirt1 pathway is activated in the small intestine of mice after II/R, and Si-based agent can further activate this pathway, alleviating intestinal injury, inhibiting apoptosis, reversing inflammation and oxidative stress, and suppressing ferroptosis in mice after II/R. Furthermore, by administering AMPK agonists and inhibitors, as well as ferroptosis inhibitors for further exploration, we discovered that the hydrogen generated by Si-based agent may inhibit ferroptosis and alleviate II/R injury through the AMPK-Sirt1 signaling pathway. This study provides theoretical and experimental evidence for elucidating the pathogenesis of intestinal ischemia/reperfusion injury and for the clinical application of Si-based agent.
- 19 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessSilicon-based agent alleviating intestinal ischemia/reperfusion injury in mice by inhibiting ferroptosis via activating AMPK-Sirt1 signaling pathway
Ferroptosis is a death mode centered on iron metabolism and lipid peroxidation pathways. Recent studies have shown that inhibiting ferroptosis can alleviate intestinal ischemia/reperfusion (II/R) injury. Hydrogen (H2) can mitigate II/R injury by anti-oxidative stress, while Silicon (Si)-based agent can generate a large amount of H2 in the alkaline environment of the intestine during II/R. However, it is unclear whether Si-based agent can alleviate II/R injury. By establishing a mouse model of II/R injury, we examined the histopathological changes, apoptosis, inflammatory factors, oxidative stress, and ferroptosis levels in the small intestine. We found that the AMPK-Sirt1 pathway is activated in the small intestine of mice after II/R, and Si-based agent can further activate this pathway, alleviating intestinal injury, inhibiting apoptosis, reversing inflammation and oxidative stress, and suppressing ferroptosis in mice after II/R. Furthermore, by administering AMPK agonists and inhibitors, as well as ferroptosis inhibitors for further exploration, we discovered that the hydrogen generated by Si-based agent may inhibit ferroptosis and alleviate II/R injury through the AMPK-Sirt1 signaling pathway. This study provides theoretical and experimental evidence for elucidating the pathogenesis of intestinal ischemia/reperfusion injury and for the clinical application of Si-based agent.
- 11 September 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-14
Beyond inflammation: a comprehensive microglial regulation model in chronic pain
Chronic pain has emerged as a disorder of persistent neuroimmune dysregulation, with microglia playing a pivotal role in shaping maladaptive plasticity. Beyond classical inflammatory pathways, recent discoveries highlight microglial involvement in epigenetic remodeling, metabolic reprogramming, and synaptic modulation. These multidimensional processes sustain microglial activation and promote central sensitization, even in the absence of ongoing peripheral injury. This review proposes a comprehensive framework for understanding microglial regulation in chronic pain, emphasizing the failure of immune tolerance, aberrant neuron–glia signaling, and the emergence of disease-perpetuating microglial states. We further discuss therapeutic strategies aimed at selectively targeting microglial phenotypes, including HDAC inhibitors, metabolic modulators, and pathway-specific antagonists. By integrating mechanistic depth with translational insights, this review reframes microglia not only as inflammatory mediators, but as dynamic regulators whose dysregulation underlies pain chronification.
- 11 September 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-14
Beyond inflammation: a comprehensive microglial regulation model in chronic pain
Chronic pain has emerged as a disorder of persistent neuroimmune dysregulation, with microglia playing a pivotal role in shaping maladaptive plasticity. Beyond classical inflammatory pathways, recent discoveries highlight microglial involvement in epigenetic remodeling, metabolic reprogramming, and synaptic modulation. These multidimensional processes sustain microglial activation and promote central sensitization, even in the absence of ongoing peripheral injury. This review proposes a comprehensive framework for understanding microglial regulation in chronic pain, emphasizing the failure of immune tolerance, aberrant neuron–glia signaling, and the emergence of disease-perpetuating microglial states. We further discuss therapeutic strategies aimed at selectively targeting microglial phenotypes, including HDAC inhibitors, metabolic modulators, and pathway-specific antagonists. By integrating mechanistic depth with translational insights, this review reframes microglia not only as inflammatory mediators, but as dynamic regulators whose dysregulation underlies pain chronification.
- 10 July 2025
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 83 (4) , 4163-4180
Beyond Paradox: Ozone Therapy as a Hormetic Modulator in Ischemia-Reperfusion Injury - An Update
Ischemia-reperfusion injury (IRI) represents a significant clinical challenge characterized by mitochondrial dysfunction and redox imbalance during blood flow restoration following ischemia. This review provides a critical analysis of ozone therapy’s emerging role in IRI management through its unique hormetic properties. Recent research has transformed our understanding of ozone—traditionally considered harmful—revealing that controlled administration demonstrates remarkable therapeutic potential through dose-dependent effects. Quantitative analysis reveals that low-dose ozone exposure (10–40 µg/mL) significantly reduces oxidative stress markers while increasing antioxidant enzyme activity across multiple organ systems. The protective effects manifest primarily through enhanced Nuclear factor erythroid 2-related factor 2 activity, orchestrating upregulation of key protective enzymes while suppressing excessive nuclear factor kappa B mediated inflammation. Current evidence demonstrates consistent protective effects across cardiovascular, digestive, urogenital, and cerebral systems, with effect sizes ranging from moderate to large. However, critical analysis reveals significant limitations including predominant reliance on animal models (>95% of studies), lack of standardized protocols, and limited human clinical data. Safety assessment indicates a narrow therapeutic window, with beneficial effects observed at 10–40 µg/mL but potential toxicity at doses >80 µg/mL. This review establishes that while ozone therapy shows promising experimental efficacy in IRI through hormetic modulation of cellular stress responses, substantial research gaps exist regarding optimal dosing, administration protocols, and long-term safety. Future clinical translation requires rigorous standardization of therapeutic parameters, comprehensive safety assessment, and well-designed human trials to validate experimental findings. Graphical Abstract
- 10 July 2025
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 83 (4) , 4163-4180
Beyond Paradox: Ozone Therapy as a Hormetic Modulator in Ischemia-Reperfusion Injury - An Update
Ischemia-reperfusion injury (IRI) represents a significant clinical challenge characterized by mitochondrial dysfunction and redox imbalance during blood flow restoration following ischemia. This review provides a critical analysis of ozone therapy’s emerging role in IRI management through its unique hormetic properties. Recent research has transformed our understanding of ozone—traditionally considered harmful—revealing that controlled administration demonstrates remarkable therapeutic potential through dose-dependent effects. Quantitative analysis reveals that low-dose ozone exposure (10–40 µg/mL) significantly reduces oxidative stress markers while increasing antioxidant enzyme activity across multiple organ systems. The protective effects manifest primarily through enhanced Nuclear factor erythroid 2-related factor 2 activity, orchestrating upregulation of key protective enzymes while suppressing excessive nuclear factor kappa B mediated inflammation. Current evidence demonstrates consistent protective effects across cardiovascular, digestive, urogenital, and cerebral systems, with effect sizes ranging from moderate to large. However, critical analysis reveals significant limitations including predominant reliance on animal models (>95% of studies), lack of standardized protocols, and limited human clinical data. Safety assessment indicates a narrow therapeutic window, with beneficial effects observed at 10–40 µg/mL but potential toxicity at doses >80 µg/mL. This review establishes that while ozone therapy shows promising experimental efficacy in IRI through hormetic modulation of cellular stress responses, substantial research gaps exist regarding optimal dosing, administration protocols, and long-term safety. Future clinical translation requires rigorous standardization of therapeutic parameters, comprehensive safety assessment, and well-designed human trials to validate experimental findings. Graphical Abstract
- 8 July 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 681
MicroRNA-451: A multifaceted regulator in cerebral and cardiac ischemia-reperfusion injury - from molecular mechanisms to therapeutic potential
Ischemia-reperfusion injury (IRI) represents a major clinical challenge across various organ systems, with especially severe and often irreversible consequences in cardiac and cerebral tissues. Despite advances in understanding its pathophysiology, effective therapeutic strategies remain limited. MicroRNA-451 (miR-451), a highly conserved non-coding RNA located on human chromosome 17q11.2, has emerged as a critical regulator of key pathophysiological processes underlying IRI, including inflammation, immune cell function, oxidative stress, and programmed cell death. This review comprehensively examines the complex and sometimes paradoxical roles of miR-451 in cardiac and cerebral IRI. We explore miR-451's potential as both a diagnostic biomarker and therapeutic target in IRI management, highlighting innovative approaches such as exosome-mediated miR-451 delivery. Finally, we address critical challenges in translating miR-451-based therapies to clinical practice and outline promising directions for future research. This comprehensive analysis provides a theoretical framework for developing novel miR-451-focused strategies for IRI detection and treatment, with significant implications for improving outcomes in ischemic disorders.
- 8 July 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 681
MicroRNA-451: A multifaceted regulator in cerebral and cardiac ischemia-reperfusion injury - from molecular mechanisms to therapeutic potential
Ischemia-reperfusion injury (IRI) represents a major clinical challenge across various organ systems, with especially severe and often irreversible consequences in cardiac and cerebral tissues. Despite advances in understanding its pathophysiology, effective therapeutic strategies remain limited. MicroRNA-451 (miR-451), a highly conserved non-coding RNA located on human chromosome 17q11.2, has emerged as a critical regulator of key pathophysiological processes underlying IRI, including inflammation, immune cell function, oxidative stress, and programmed cell death. This review comprehensively examines the complex and sometimes paradoxical roles of miR-451 in cardiac and cerebral IRI. We explore miR-451's potential as both a diagnostic biomarker and therapeutic target in IRI management, highlighting innovative approaches such as exosome-mediated miR-451 delivery. Finally, we address critical challenges in translating miR-451-based therapies to clinical practice and outline promising directions for future research. This comprehensive analysis provides a theoretical framework for developing novel miR-451-focused strategies for IRI detection and treatment, with significant implications for improving outcomes in ischemic disorders.
- 26 June 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-15
Molecular hydrogen as a novel regulator of cellular pyroptosis: mechanistic insights and therapeutic implications
Pyroptosis, a highly inflammatory programmed cell death pathway, drives pathogenesis in numerous diseases through gasdermin-mediated membrane pore formation and massive cytokine release. While conventional anti-inflammatory therapies show limited efficacy, hydrogen emerges as a novel therapeutic agent with unique pyroptosis-regulatory capabilities. This review establishes a comprehensive mechanistic framework demonstrating that hydrogen modulates pyroptosis through interconnected pathways including direct gasdermin redox modification, mitochondrial signaling integration, and inflammasome assembly disruption. Systematic analysis across diverse disease models—cardiac ischemia-reperfusion, neuroinflammation, metabolic dysfunction, and cancer—reveals hydrogen’s remarkable context-dependent effects: cytoprotective in normal tissues while promoting therapeutic pyroptosis in malignant cells. Hydrogen’s regulatory mechanisms exhibit striking tissue specificity and temporal complexity, with immediate antioxidant effects transitioning to sustained anti-inflammatory responses. Despite compelling preclinical evidence demonstrating efficacy in myocardial injury, neurodegeneration, and systemic inflammation, significant translational barriers remain including delivery optimization, dosimetric standardization, and biomarker development. This review critically evaluates hydrogen’s transformative therapeutic potential while addressing realistic implementation challenges, providing a roadmap for advancing this innovative paradigm from bench to bedside.
- 26 June 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-15
Molecular hydrogen as a novel regulator of cellular pyroptosis: mechanistic insights and therapeutic implications
Pyroptosis, a highly inflammatory programmed cell death pathway, drives pathogenesis in numerous diseases through gasdermin-mediated membrane pore formation and massive cytokine release. While conventional anti-inflammatory therapies show limited efficacy, hydrogen emerges as a novel therapeutic agent with unique pyroptosis-regulatory capabilities. This review establishes a comprehensive mechanistic framework demonstrating that hydrogen modulates pyroptosis through interconnected pathways including direct gasdermin redox modification, mitochondrial signaling integration, and inflammasome assembly disruption. Systematic analysis across diverse disease models—cardiac ischemia-reperfusion, neuroinflammation, metabolic dysfunction, and cancer—reveals hydrogen’s remarkable context-dependent effects: cytoprotective in normal tissues while promoting therapeutic pyroptosis in malignant cells. Hydrogen’s regulatory mechanisms exhibit striking tissue specificity and temporal complexity, with immediate antioxidant effects transitioning to sustained anti-inflammatory responses. Despite compelling preclinical evidence demonstrating efficacy in myocardial injury, neurodegeneration, and systemic inflammation, significant translational barriers remain including delivery optimization, dosimetric standardization, and biomarker development. This review critically evaluates hydrogen’s transformative therapeutic potential while addressing realistic implementation challenges, providing a roadmap for advancing this innovative paradigm from bench to bedside.
- Open Access
- 16 February 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (2) , 127
MiR-451 in Inflammatory Diseases: Molecular Mechanisms, Biomarkers, and Therapeutic Applications—A Comprehensive Review Beyond Oncology
MicroRNAs play crucial roles in regulating inflammatory responses and disease progression. Since its identification on chromosome 17q11.2 in 2005, miR-451 has emerged as a key regulator of multiple physiological and pathological processes. While its role in cancer has been extensively documented, accumulating evidence reveals miR-451’s broader significance in inflammatory conditions through the regulation of NF-κB, AMPK, and PI3K signaling pathways. This comprehensive review systematically analyzes miR-451’s multifaceted functions in inflammatory diseases, with particular focus on ischemia–reperfusion injury, arthritis, and acute organ injuries. We present compelling evidence for miR-451’s potential as a diagnostic biomarker, demonstrating its distinctive expression patterns across various biological specimens and disease states. Furthermore, we elucidate how miR-451 modulates inflammatory responses through the regulation of immune cell populations, including microglia activation, macrophage polarization, and neutrophil chemotaxis. By integrating current evidence and bioinformatic analyses, we establish a theoretical framework linking miR-451’s molecular mechanisms to its therapeutic applications. This review not only synthesizes the current understanding of miR-451 in inflammatory diseases but also provides critical insights for developing novel diagnostic tools and therapeutic strategies.
- 16 February 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (2) , 127
Open AccessMiR-451 in Inflammatory Diseases: Molecular Mechanisms, Biomarkers, and Therapeutic Applications—A Comprehensive Review Beyond Oncology
MicroRNAs play crucial roles in regulating inflammatory responses and disease progression. Since its identification on chromosome 17q11.2 in 2005, miR-451 has emerged as a key regulator of multiple physiological and pathological processes. While its role in cancer has been extensively documented, accumulating evidence reveals miR-451’s broader significance in inflammatory conditions through the regulation of NF-κB, AMPK, and PI3K signaling pathways. This comprehensive review systematically analyzes miR-451’s multifaceted functions in inflammatory diseases, with particular focus on ischemia–reperfusion injury, arthritis, and acute organ injuries. We present compelling evidence for miR-451’s potential as a diagnostic biomarker, demonstrating its distinctive expression patterns across various biological specimens and disease states. Furthermore, we elucidate how miR-451 modulates inflammatory responses through the regulation of immune cell populations, including microglia activation, macrophage polarization, and neutrophil chemotaxis. By integrating current evidence and bioinformatic analyses, we establish a theoretical framework linking miR-451’s molecular mechanisms to its therapeutic applications. This review not only synthesizes the current understanding of miR-451 in inflammatory diseases but also provides critical insights for developing novel diagnostic tools and therapeutic strategies.
- Open Access
- 12 September 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (2) , 1532-1533
A safe and comfortable radial-artery catheterization method for invasive blood pressure monitoring
- 12 September 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (2) , 1532-1533
Open AccessA safe and comfortable radial-artery catheterization method for invasive blood pressure monitoring
- Open Access
- 1 January 2024
- Published by MRE Press in Signa Vitae
- Vol. 20 (4) , 1-14
Norepinephrine versus phenylephrine for managing maternal hypotension during cesarean delivery under spinal anesthesia: a meta-analysis of maternal and neonatal outcomes
Norepinephrine or phenylephrine administration to prevent and treat hypotension during spinal anesthesia for cesarean section has been a significant topic of discussion. This meta-analysis aimed to update existing evidence and provide further insights into neonatal and maternal outcomes associated with norepinephrine and phenylephrine. Review of randomized controlled trials (RCTs) was performed to assess the effectiveness of norepinephrine and phenylephrine in managing maternal hypotension during cesarean delivery under spinal anesthesia. Neonatal umbilical cord blood pH and maternal hypotension were the primary outcomes. Based on the analysis of 26 RCTs with 2984 participants, we found no significant difference between the norepinephrine and phenylephrine groups in umbilical artery pH in neonates (mean difference (MD) 0.00; 95% confidence interval (CI) −0.00 to 0.01, p = 0.20). Neonates Apgar scores did not differ between both groups. Norepinephrine was associated with lower incidences of bradycardia (risk ratio (RR) 0.44; 95% CI 0.37 to 0.51, p < 0.001) and reactive hypertension (RR 0.53; 95% CI 0.39 to 0.72, p < 0.001) in parturient women than phenylephrine. In neither group did umbilical cord blood levels of partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2) and base excess (BE) levels of neonates differ significantly, nor did maternal hypotension, nausea or vomiting incidence during delivery. For maternal hypotension after spinal anesthesia, norepinephrine and phenylephrine did not significantly differ in neonatal acidemia. Despite similarities to phenylephrine in managing hypotension and maintaining maternal hemodynamic stability, norepinephrine is a promising alternative.
- 1 January 2024
- Published by MRE Press in Signa Vitae
- Vol. 20 (4) , 1-14
Open AccessNorepinephrine versus phenylephrine for managing maternal hypotension during cesarean delivery under spinal anesthesia: a meta-analysis of maternal and neonatal outcomes
Norepinephrine or phenylephrine administration to prevent and treat hypotension during spinal anesthesia for cesarean section has been a significant topic of discussion. This meta-analysis aimed to update existing evidence and provide further insights into neonatal and maternal outcomes associated with norepinephrine and phenylephrine. Review of randomized controlled trials (RCTs) was performed to assess the effectiveness of norepinephrine and phenylephrine in managing maternal hypotension during cesarean delivery under spinal anesthesia. Neonatal umbilical cord blood pH and maternal hypotension were the primary outcomes. Based on the analysis of 26 RCTs with 2984 participants, we found no significant difference between the norepinephrine and phenylephrine groups in umbilical artery pH in neonates (mean difference (MD) 0.00; 95% confidence interval (CI) −0.00 to 0.01, p = 0.20). Neonates Apgar scores did not differ between both groups. Norepinephrine was associated with lower incidences of bradycardia (risk ratio (RR) 0.44; 95% CI 0.37 to 0.51, p < 0.001) and reactive hypertension (RR 0.53; 95% CI 0.39 to 0.72, p < 0.001) in parturient women than phenylephrine. In neither group did umbilical cord blood levels of partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2) and base excess (BE) levels of neonates differ significantly, nor did maternal hypotension, nausea or vomiting incidence during delivery. For maternal hypotension after spinal anesthesia, norepinephrine and phenylephrine did not significantly differ in neonatal acidemia. Despite similarities to phenylephrine in managing hypotension and maintaining maternal hemodynamic stability, norepinephrine is a promising alternative.
- 16 March 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 117, 110033
Amelioration of nerve demyelination by hydrogen-producing silicon-based agent in neuropathic pain rats
- 16 March 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 117, 110033
Amelioration of nerve demyelination by hydrogen-producing silicon-based agent in neuropathic pain rats
- 6 October 2021
- Published by Springer Nature in Spinal Cord
- Vol. 60 (4) , 326-331
Ischemic postconditioning reduces spinal cord ischemia-reperfusion injury through ATP-sensitive potassium channel
Study design Animal study. Objectives Explore the neuroprotective effect of remote limb ischemic postconditioning (Post C) in spinal cord ischemic reperfusion injury (SCII) and related mechanisms. Setting Anesthesiology Laboratory of Southwest Medical University. Methods We established a rabbit SCII model and processed it with Post C. To evaluate the neural function, spinal cord tissue was taken 48 h later, normal neurons were evaluated by HE staining, and the expression of ATP-sensitive potassium channel (KATP) marker molecule Kir6.2 was detected by Western blot. Immunofluorescence detection of spinal cord Iba-1 expression, ELISA detection of M1 type microglia marker iNOS and M2 type microglia marker Arg, and Western blot detection of NF-κB and IL-1β expression. Through these experiments, we will explore the protective effect of Post C in SCII, observe the changes in the protective effect after using KATP blockers, and verify that Post C can play a neuroprotective effect in SCII by activating KATP. Results We observed that Post C significantly improved exercise ability and the number of spinal motor neurons in the SCII model. Microglia are activated and expression of M1 microglia in the spinal cord was decreased, while M2 was increased. This neuroprotective effect was reversed by the nonspecific KATP inhibitor. Conclusion Post C has a neuroprotective effect on SCII, and maybe a protective effect produced by activating KATP to regulate spinal microglia polarization and improve neuroinflammation.
- 6 October 2021
- Published by Springer Nature in Spinal Cord
- Vol. 60 (4) , 326-331
Ischemic postconditioning reduces spinal cord ischemia-reperfusion injury through ATP-sensitive potassium channel
Study design Animal study. Objectives Explore the neuroprotective effect of remote limb ischemic postconditioning (Post C) in spinal cord ischemic reperfusion injury (SCII) and related mechanisms. Setting Anesthesiology Laboratory of Southwest Medical University. Methods We established a rabbit SCII model and processed it with Post C. To evaluate the neural function, spinal cord tissue was taken 48 h later, normal neurons were evaluated by HE staining, and the expression of ATP-sensitive potassium channel (KATP) marker molecule Kir6.2 was detected by Western blot. Immunofluorescence detection of spinal cord Iba-1 expression, ELISA detection of M1 type microglia marker iNOS and M2 type microglia marker Arg, and Western blot detection of NF-κB and IL-1β expression. Through these experiments, we will explore the protective effect of Post C in SCII, observe the changes in the protective effect after using KATP blockers, and verify that Post C can play a neuroprotective effect in SCII by activating KATP. Results We observed that Post C significantly improved exercise ability and the number of spinal motor neurons in the SCII model. Microglia are activated and expression of M1 microglia in the spinal cord was decreased, while M2 was increased. This neuroprotective effect was reversed by the nonspecific KATP inhibitor. Conclusion Post C has a neuroprotective effect on SCII, and maybe a protective effect produced by activating KATP to regulate spinal microglia polarization and improve neuroinflammation.